
WEBINAR
Only
Pulmonary Hypertension: Beyond Vasodilators
Tuesday, October 12, 2021, 11:00 AM - 5:00 PM EDT
Webinar
Pulmonary hypertension (PH) is a highly morbid condition without cure. Some forms of PH, such as Pulmonary Arterial Hypertension (PAH) have a mean survival of 5-years after diagnosis with mortality most commonly due to right heart failure. Current therapies include several classes of vasodilators, including prostacyclins, calcium channel blockers, PDE5 inhibitors, endothelin receptor antagonists (ETRA), and soluble guanylate cyclase stimulators, all of which are limited by systemic hypotension. Several agents including ETRA and prostacyclin have additional dose-limiting systemic side effects or toxicities. Moreover, many patients are unresponsive to these agents at diagnosis or during the course of therapy, due to advanced disease, progression, or drug tachyphylaxis. Given these limitations, there is a strong need for new therapies beyond vasodilators acting by novel anti-proliferative, antifibrotic, or anti-inflammatory mechanisms to modify the natural history of disease. This virtual symposium will convene basic researchers, clinicians, and drug developers to discuss latest advances in the development of novel therapeutics that can overcome the limitations of current therapy for PH.